Principal Healthcare Innovators ETF
The investment seeks to provide investment results that closely correspond, before expenses, to the performance of the Nasdaq Healthcare Innovators Index (the "index"). Under normal circumstances, the fund invests at least 80% of its net assets, plus any borrowings for investment purposes, in equity securities of companies that compose the index at the time of purchase. The index uses a quantitative model designed to identify equity securities in the Nasdaq US Benchmark Index that are small and medium capitalization U.S. healthcare companies.
Seeks to tap into the increasing demand for healthcare solutions as demographic trends have driven healthcare spending to more than double in the last 20 years.1
Specialized healthcare solution
Brings an efficient, systematic approach to identifying and selecting smaller healthcare companies that many investors neglect.
Invests in companies that are leading the charge toward innovative solutions, rather than spending money on marketing and distribution.
Daily as of 5/18/2022 unless otherwise stated
Net Asset Value (NAV)
NAV Per Share Ticker
Intraday NAV Ticker
Shares Outstanding Ticker
30 Day SEC Yield as of 4/30/2022
Total Cash Ticker
Investment Manager or Sub-advisor
Principal Global Investors, LLC
Aaron Siebel since 3/3/2020
Jeffrey Schwarte since 8/19/2016
|Average Annual Total Returns||1 Month||3 Month||YTD||1 Year||3 Year||5 Year||10 Year||Since Inception*|
|Net Asset Value (NAV) Return||-17.12||-16.70||-30.56||-44.75||0.38||4.07||N/A||5.20|
|Market Price Return||-16.95||-16.42||-30.37||-44.77||0.44||4.11||N/A||5.22|
|Nasdaq US Health Care Innovators Index||-17.14||-16.68||-30.54||-44.59||0.69||4.46||N/A||5.61|
|# of Funds in Category||184||183||181||167||142||132||109||43|
|Morningstar Percentile Rankings||N/A||N/A||N/A||94||88||86||N/A||N/A|
|Average Annual Total Returns||1 Month||3 Month||YTD||1 Year||3 Year||5 Year||10 Year||Since Inception*|
|Net Asset Value (NAV) Return||1.36||-16.22||-16.22||-30.74||4.97||8.47||N/A||8.86|
|Market Price Return||1.25||-16.16||-16.16||-30.41||4.95||8.47||N/A||8.84|
|Nasdaq US Health Care Innovators Index||1.38||-16.17||-16.17||-30.50||5.32||8.89||N/A||9.30|
|Calendar Year Total Returns||2021||2020||2019||2018||2017|
|Net Asset Value (NAV) Return||-18.44||52.52||38.92||-11.20||36.31|
|Market Price Return||-18.58||52.53||39.08||-11.47||36.53|
|Nasdaq US Health Care Innovators Index||-18.15||52.90||39.58||-10.82||36.99|
*Inception date: 8/19/2016
Some data is provided by Morningstar and is the most current information available. As of 5/17/2022
Morningstar percentile rankings are based on total returns.
Investment results shown represent historical performance and do not guarantee future results. Investment returns and principal values fluctuate with changes in interest rates and other market conditions so the value, when redeemed, may be worth more or less than original costs. Current performance may be lower or higher than the performance data shown.
|Ex-Date||Type||$ Per Share|
|Ex-Date12/29/2021||TypeIncome||$ Per Share0.453223|
|Ex-Date12/17/2020||TypeShort Term Capital Gain||$ Per Share0.215423|
Dividends are paid quarterly.
|Total Investment Expense - Net:||0.42|
|Total Investment Expense - Gross:||0.42|
|Expense Waiver Date:||N/A|
|Contractual Cap Date:||N/A|
Premium / Discount to NAV as of 3/31/2022
|Q1 2021||Q2 2021||Q3 2021||Q4 2021||Q1 2022|
|Days Traded At Premium||Q1 202150||Q2 202139||Q3 202133||Q4 202117||Q1 202224|
|Days Traded At Discount||Q1 202111||Q2 202124||Q3 202131||Q4 202147||Q1 202238|
Fund Informationas of 4/30/2022
|3 Year||5 Year|
Inception Date: 8/19/2016
Risk and return statistical data is calculated by Principal Global Investors.
Fund Informationas of 5/17/2022
|Average Market Cap (mil):||$3,301.28|
|Price/Cash Flow Ratio:||11.38|
|# Stock Holdings:||282|
|# Bond Holdings:||0|
|# Other Holdings:||1|
|# Total Holdings:||283|
Top 10 Holdingsas of 5/18/2022
|Top 10 Holdings||Total Market Value||% of Net Assets|
|Top 10 HoldingsSEAGEN INC COMMON STOCK USD.001||Total Market Value2,078,665.20||% of Net Assets3.82%|
|Top 10 HoldingsBIOMARIN PHARMACEUTICAL INC COMMON STOCK USD.001||Total Market Value1,703,611.84||% of Net Assets3.13%|
|Top 10 HoldingsVIATRIS INC COMMON STOCK||Total Market Value1,623,750.55||% of Net Assets2.98%|
|Top 10 HoldingsALNYLAM PHARMACEUTICALS INC COMMON STOCK USD.01||Total Market Value1,618,314.65||% of Net Assets2.97%|
|Top 10 HoldingsELANCO ANIMAL HEALTH INC COMMON STOCK||Total Market Value1,340,292.80||% of Net Assets2.46%|
|Top 10 HoldingsBIOHAVEN PHARMACEUTICAL HOLD COMMON STOCK||Total Market Value1,172,520.60||% of Net Assets2.15%|
|Top 10 HoldingsEXACT SCIENCES CORP COMMON STOCK USD.01||Total Market Value1,103,302.90||% of Net Assets2.03%|
|Top 10 HoldingsJAZZ PHARMACEUTICALS PLC COMMON STOCK USD.0001||Total Market Value1,096,327.38||% of Net Assets2.01%|
|Top 10 HoldingsNEUROCRINE BIOSCIENCES INC COMMON STOCK USD.001||Total Market Value957,270.60||% of Net Assets1.76%|
|Top 10 HoldingsAGILON HEALTH INC COMMON STOCK USD.01||Total Market Value918,320.13||% of Net Assets1.69%|
Includes, but is not limited to, unsettled activity from creation/redemption transactions and portfolio security trades and accrued interest. Values may exceed 100% if both long and short positions are included in the portfolio.
Portfolio Allocationsas of 05/17/2022
|Asset TypeU.S. Bonds||Net0.00%||Short0.00%||Long0.00%|
|Asset TypeNon-U.S. Bonds||Net0.00%||Short0.00%||Long0.00%|
|Asset TypeU.S. Stocks||Net98.38%||Short0.00%||Long98.38%|
|Asset TypeNon-U.S. Stocks||Net1.32%||Short0.00%||Long1.32%|
Sector Allocationsas of 5/17/2022
Stock Sector Breakdown (% of Stocks)
|% of stocks|
Holding, portfolio and sector allocations are subject to change.
Returns shown for periods of less than one year are not annualized.
Investor shares are bought and sold at market price (not NAV) and are not individually redeemed from the Fund. Ordinary brokerage commissions apply.
Prior to 11/02/2020, the market price used to disclose the daily price and calculate daily premiums and discounts was the midpoint between the highest bid and the lowest offer on the exchange on which the shares of the Fund are listed for trading, as of the time that the Fund's NAV is calculated. Beginning on 11/02/2020, the market price used to disclose the daily price and calculate daily premiums and discounts is the official closing price of the Fund, or if it more accurately reflects the market value of the Fund share at the time as of which the Fund’s NAV is calculated, the price that is the midpoint between the national best bid and national best offer as of that time. For the purpose of calculating Market Price Return, a market price prior to 02/01/2021 is defined as the midpoint between the highest bid and the lowest offer on the exchange on which the shares of the Fund are listed for trading, as of the time that the Fund’s NAV is calculated while a market price on or after 02/01/2021 is defined as the official close price as of the time that the Fund's NAV is calculated. If you trade your shares at another time, your return may differ.
Where gross and net expense ratios differ, the investment adviser has contractually agreed to limit the investment option's expenses. Differences also may be due to the investment adviser's decision to waive (through the same dates) certain expenses that would normally be payable by the fund. The net expense figure reflects the impact of any limits or waivers. Returns displayed are based on net total investment expense.
Performance data quoted represents past performance. Past performance is no guarantee of future results and investment returns, and principal value of the Fund will fluctuate so that shares, when redeemed, may be worth more or less than their original cost. Current performance may be higher or lower than the performance quoted.
Investors should carefully consider a fund’s investment objectives, risks, charges, and expenses prior to investing.
© 2022 Morningstar, Inc. All Rights Reserved. Part of the data contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete, or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information.
The Morningstar Style Box is a nine-square grid that provides a graphical representation of the "investment style" of a fund. The Equity style box classifies securities by size along the vertical axis and by value and growth characteristics along the horizontal axis. The model for the fixed-income style box is based on the two pillars of fixed-income performance: interest-rate sensitivity and credit quality. The three interest sensitivity groups are limited, moderate and extensive and the three credit quality groups are high, medium and low. These groupings display a portfolio’s effective duration and third party credit ratings to provide an overall representation of the fund’s risk orientation given the sensitivity to interest rate and credit rating of bonds in the portfolio.
The Morningstar RatingTM for funds, or "star rating," is calculated for managed products (including mutual funds, variable annuity and variable life subaccounts, exchange-traded funds, closed-end funds, and separate accounts) with at least a three-year history. Exchange traded funds and open-ended mutual funds are considered a single population for comparative purposes. It is calculated based on a Morningstar Risk-Adjusted Return measure that accounts for variation in a managed product's monthly excess performance, placing more emphasis on downward variations and rewarding consistent performance. The top 10% of products in each product category receive 5 stars, the next 22.5% receive 4 stars, the next 35% receive 3 stars, the next 22.5% receive 2 stars, and the bottom 10% receive 1 star. The Overall Morningstar Rating for a managed product is derived from a weighted average of the performance figures associated with its three-, five-, and 10-year (if applicable) Morningstar Rating metrics. The weights are: 100% three-year rating for 36-59 months of total returns, 60% five-year rating/40% three-year rating for 60-119 months of total returns, and 50% 10-year rating/30% five-year rating/20% three-year rating for 120 or more months of total returns. While the 10-year overall star rating formula seems to give the most weight to the 10-year period, the most recent three-year period actually has the greatest impact because it is included in all three rating periods. Morningstar ratings do not reflect the inclusion of sales charges. If sales charges were reflected, ratings could be lower.
The Principal Healthcare Innovators ETF seeks to track the Nasdaq U.S. Healthcare Innovators Index, a Nasdaq-licensed index based on Principal’s intellectual property. The Nasdaq U.S. Healthcare Innovators Index is designed to provide exposure to U.S. companies that are early stage healthcare companies.
Asset allocation and diversification do not ensure a profit or protect against a loss. Investing in ETFs involves risk, including possible loss of principal. ETFs are subject to risk similar to those of stocks, including those regarding short-selling and margin account maintenance.
Equity investments involve greater risk, including higher volatility, than fixed-income investment options.
Small and mid-cap stocks may have additional risks including greater price volatility.
Investments concentrated in the healthcare industry may be adversely impacted by sector specific market shocks, unforeseen rate controls or regulations, higher than expected costs, or inability to bring new products to market.
**During extraordinary market conditions, the index provider may delay the scheduled rebalancing of the index until a future date when conditions have changed.
Effective October 29, 2021, the Principal Healthcare Innovators Index ETF was renamed to the Principal Healthcare Innovators ETF.
Morningstar Star Rating
This is a proprietary Morningstar data point.
Morningstar rates mutual funds and ETFs from 1 to 5 stars based on how well they've performed (after adjusting for risk and accounting for sales charges) in comparison to similar funds and ETFs.
Within each Morningstar Category, the top 10% of funds and ETFs receive 5 stars and the bottom 10% receive 1 star. Funds and ETFs are rated for up to three time periods-three-, five-, and 10-years and these ratings are combined to produce an overall rating. Funds and ETFs with less than three years of history are not rated.
Ratings are objective, based entirely on a mathematical evaluation of past performance. They're a useful tool for identifying funds and ETFs worthy of further research, but shouldn't be considered buy or sell signals.